Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
MDXG's Cash to Debt is ranked higher than
93% of the 392 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. MDXG: No Debt )
MDXG' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: No Debt

Equity to Asset 0.87
MDXG's Equity to Asset is ranked higher than
92% of the 373 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. MDXG: 0.87 )
MDXG' s 10-Year Equity to Asset Range
Min: 0.44   Max: 0.89
Current: 0.87

0.44
0.89
F-Score: 7
Z-Score: 39.08
M-Score: -2.21
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -125.79
MDXG's Operating margin (%) is ranked lower than
53% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. MDXG: -125.79 )
MDXG' s 10-Year Operating margin (%) Range
Min: -1334.98   Max: -4.46
Current: -125.79

-1334.98
-4.46
Net-margin (%) -131.37
MDXG's Net-margin (%) is ranked lower than
52% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 4.71 vs. MDXG: -131.37 )
MDXG' s 10-Year Net-margin (%) Range
Min: -1447.4   Max: -6.95
Current: -131.37

-1447.4
-6.95
ROE (%) -85.69
MDXG's ROE (%) is ranked lower than
55% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 5.57 vs. MDXG: -85.69 )
MDXG' s 10-Year ROE (%) Range
Min: -566.67   Max: -5.59
Current: -85.69

-566.67
-5.59
ROA (%) -37.62
MDXG's ROA (%) is ranked lower than
51% of the 392 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. MDXG: -37.62 )
MDXG' s 10-Year ROA (%) Range
Min: -155.33   Max: -4.86
Current: -37.62

-155.33
-4.86
ROC (Joel Greenblatt) (%) -1123.25
MDXG's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 391 Companies
in the Global Medical Devices industry.

( Industry Median: 12.89 vs. MDXG: -1123.25 )
MDXG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1391.41   Max: -16.71
Current: -1123.25

-1391.41
-16.71
Revenue Growth (%) 293.60
MDXG's Revenue Growth (%) is ranked higher than
100% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. MDXG: 293.60 )
MDXG' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 293.6
Current: 293.6

0
293.6
EBITDA Growth (%) -60.30
MDXG's EBITDA Growth (%) is ranked lower than
51% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -2.90 vs. MDXG: -60.30 )
MDXG' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 81.7
Current: -60.3

0
81.7
EPS Growth (%) -40.50
MDXG's EPS Growth (%) is ranked higher than
52% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: -2.00 vs. MDXG: -40.50 )
MDXG' s 10-Year EPS Growth (%) Range
Min: -40.5   Max: 260
Current: -40.5

-40.5
260
» MDXG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

MDXG Guru Trades in

Q4 2013

MDXG Guru Trades in Q4 2013

Steven Cohen 898,000 sh (New)
Jim Simons 100,350 sh (New)
Caxton Associates 50,000 sh (New)
» More
Q1 2014

MDXG Guru Trades in Q1 2014

Steven Cohen 1,035,000 sh (+15.26%)
Jim Simons Sold Out
Caxton Associates Sold Out
» More
Q2 2014

MDXG Guru Trades in Q2 2014

Jim Simons 179,900 sh (New)
Steven Cohen 906,800 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MDXG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.06
MDXG's P/B is ranked lower than
67% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. MDXG: 10.06 )
MDXG' s 10-Year P/B Range
Min: 5.5   Max: 21.82
Current: 10.06

5.5
21.82
P/S 9.03
MDXG's P/S is ranked lower than
60% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 3.21 vs. MDXG: 9.03 )
MDXG' s 10-Year P/S Range
Min: 6.84   Max: 148
Current: 9.03

6.84
148
EV-to-EBIT -237.99
MDXG's EV-to-EBIT is ranked lower than
51% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 57.01 vs. MDXG: -237.99 )
MDXG' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -237.99

Current Ratio 6.69
MDXG's Current Ratio is ranked higher than
92% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. MDXG: 6.69 )
MDXG' s 10-Year Current Ratio Range
Min: 0.05   Max: 7.08
Current: 6.69

0.05
7.08
Quick Ratio 6.26
MDXG's Quick Ratio is ranked higher than
93% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. MDXG: 6.26 )
MDXG' s 10-Year Quick Ratio Range
Min: 0.05   Max: 6.7
Current: 6.26

0.05
6.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 27.08
MDXG's Price/Net Cash is ranked higher than
89% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDXG: 27.08 )
MDXG' s 10-Year Price/Net Cash Range
Min: 20.43   Max: 140
Current: 27.08

20.43
140
Price/Net Current Asset Value 16.37
MDXG's Price/Net Current Asset Value is ranked higher than
86% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDXG: 16.37 )
MDXG' s 10-Year Price/Net Current Asset Value Range
Min: 13.62   Max: 140
Current: 16.37

13.62
140
Price/Tangible Book 12.57
MDXG's Price/Tangible Book is ranked higher than
58% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 6.09 vs. MDXG: 12.57 )
MDXG' s 10-Year Price/Tangible Book Range
Min: 10.57   Max: 237.5
Current: 12.57

10.57
237.5
Price/DCF (Projected) 352.00
MDXG's Price/DCF (Projected) is ranked higher than
76% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDXG: 352.00 )
MDXG' s 10-Year Price/DCF (Projected) Range
Min: 354.5   Max: 354.5
Current: 352

Price/Median PS Value 0.70
MDXG's Price/Median PS Value is ranked higher than
93% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 1.15 vs. MDXG: 0.70 )
MDXG' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 9.64
Current: 0.7

0.57
9.64

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:MXE.Germany
MiMedx Group, Inc., was incorporated in Florida on February 28, 2008. It is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membrane. Its biomaterial platform technologies include the device technologies HydroFix and CollaFixM, and its tissue technologies, AmnioFix and EpiFix. It is a supplier of allografts processed from amniotic tissue, having supplied over 120,000 allografts to date for application in the Surgical, Orthopedic, Spinal, Wound Care, Ophthalmic, and Dental segments of healthcare. The first clinical uses of fresh amnion were for wound care patients and burn victims. Its technology and products are AmnioFix, EpiFix and other Tissue -Based Allografts and Medical Devices- CollaFix and HydroFix. There have been over 150 publications on the use of amniotic membrane for uses from wound care to gingival recession and from pterygium repair to the reduction of fibrous tissue following spinal surgery. The amniotic membrane has been shown to reduce inflammation, down regulate scar tissue and promote the regeneration of soft tissues. The Company operates a licensed tissue bank. The Company is a regenerative biomaterials company with three platform technologies. Its addressable market is in chronic wound care consisting of diabetic, venous and pressure ulcers. The Orthopedic, General Surgery, Urology and OB/GYN soft tissue repair markets also represent market opportunities. In 2012, the Company established a direct sales force for Government accounts and is developing a direct sales force for commercial wound care.
» More Articles for MDXG

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
MIMEDX GROUP, INC. Financials Aug 19 2014
MIMEDX GROUP, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2014
MiMedx To Present At 34th Annual Canaccord|Genuity Growth Conference Aug 04 2014
MIMEDX GROUP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jul 31 2014
MiMedx Group Inc Earnings Call scheduled for 10:30 am ET today Jul 29 2014
MIMEDX GROUP, INC. Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial... Jul 29 2014
Q2 2014 MiMedx Group Inc Earnings Release - After Market Close Jul 29 2014
/C O R R E C T I O N -- MiMedx Group, Inc./ Jul 28 2014
MIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 28 2014
MiMedx Files Its Initial Investigational New Drug Application Jul 23 2014
Restrospective Analysis Finds MiMedx EpiFix® As Most Effective In Rapid Resolution Of Diabetic Foot... Jul 22 2014
MiMedx Announces Release Date For 2014 Second Quarter Results Jul 15 2014
Coverage initiated on MiMedx Group by Needham Jul 15 2014
MiMedx Announces Revised Local Coverage Determination From Medicare Contractor That Includes... Jul 14 2014
MiMedx Expects To File Its First Investigational New Drug Application In July Jun 19 2014
MiMedx Increases Guidance For Second Quarter And Full Year 2014 Jun 19 2014
MiMedx Board Applauds Dismissal Of Lawsuit Against Chairman & CEO Jun 04 2014
SEC Dismisses Case Against Parker H. "Pete" Petit Jun 04 2014
MiMedx still a top pick, says Canaccord May 28 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK